First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

被引：2

作者：

Ricciuti, Biagio ^{[1
]}

Chiari, Rita ^{[1
]}

机构：

[1] Univ Perugia, Santa Maria Misericordia Hosp, Dept Med Oncol, Perugia, Italy

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷

关键词：

CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; AZD9291;

D O I：

10.21037/tlcr.2018.03.06

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S127 / S130

页数：4

共 50 条

[41] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
Corassa, Marcelo
Abreu, Rodrigo Fonseca
Cordeiro de Lima, Vladmir Claudio
Torrezan, Giovana Tardim
Cavalher, Felicia Peterson
Silva, Tullio Novaes
de Oliveira, Thiago Bueno
Freitas, Helano Carioca
Carraro, Dirce Maria
Costa, Felipe D'Almeida
JCO PRECISION ONCOLOGY, 2022, 6
[42] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Ho, Gwo-Fuang
Chai, Chee-Shee
Alip, Adlinda
Wahid, Mohd Ibrahim A.
Abdullah, Matin Mellor
Foo, Yoke-Ching
How, Soon-Hin
Zaatar, Adel
Lam, Kai-Seng
Leong, Kin-Wah
Low, John-Seng-Hooi
Yusof, Mastura Md
Lee, Erica Chai-Yong
Toh, Yok-Yong
Liam, Chong-Kin
BMC CANCER, 2019, 19 (01)
[43] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Gwo-Fuang Ho
Chee-Shee Chai
Adlinda Alip
Mohd Ibrahim A. Wahid
Matin Mellor Abdullah
Yoke-Ching Foo
Soon-Hin How
Adel Zaatar
Kai-Seng Lam
Kin-Wah Leong
John-Seng-Hooi Low
Mastura Md Yusof
Erica Chai-Yong Lee
Yok-Yong Toh
Chong-Kin Liam
BMC Cancer, 19
[44] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
Wei, Fang
An, Juan
Hua, Yichun
Ding, Xiaosheng
Sun, Shibin
Li, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Remon, Jordi
Caramella, Caroline
Joelet, Cecile
Lacroix, Ludovic
Lawson, Andrew
Smalley, Sarah
Howarth, Karen
Gale, Davina
Rosenfeld, Nitzan
Green, Emma
Plagnol, Vincent
Planchard, David
Bluthgen, Maria
Gazzah, Annas
Pannet, Chloe
Nicotra, Claudio
Soria, Jean-Charles
Besse, Benjamin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
[46] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
Chen, Lanyi Nora
Lee, Alexandria T. M.
Nagasaka, Misako
Ou, Sai-Hong Ignatius
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
[47] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
Lim, Sun Min
Lee, Jii Bum
Cho, Byoung Chul
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
[48] Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Cun, F. S.
Zhang, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1586
[49] Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
Wei, Xue-Wu
Deng, Jia-Yi
Xu, Chong-Rui
Chen, Zhi-Hong
Zhu, Dong-Qin
Wu, Qian
Zhang, Xu-Chao
Wu, Yi-Long
Zhou, Qing
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (07):
[50] Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort
Piotrowska, Zofia
Chen, Lanyi Nora
Shum, Elaine
Park, Cathleen
Guo, Matthew
Liu, Ying
Tran, Misha
Marks, Jennifer Aline
Banwait, Mandeep
Liu, Stephen V.
Scott, Susan Combs
Bestvina, Christine M.
Riess, Jonathan W.
Marrone, Kristen A.
Hall, Richard Delmar
Gentzler, Ryan D.
Shu, Catherine A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →